Literature DB >> 7272175

Acetanilide and paracetamol pharmacokinetics before and during phenytoin administration: genetic control of induction?

J L Cunningham, D A Evans.   

Abstract

1 Steady state plasma concentrations (SSPCs) of acetanilide (AA) and its metabolite, paracetamol (PL), were studied in 27 healthy volunteer subjects before and at the end of an 11-day exposure to phenytoin (DPH). Plasma concentrations of DPH were estimated. Plasma concentrations of DPH varied from 5.1 to 20.4 microgram ml-1 (mean +/- s.e.mean 12.2 +/- 0.9). 2 The SSPC of AA before exposure to DPH varied from 0.06 to 0.67 microgram ml-1 (mean +/- s.e.mean 0.24 +/- 0.02), and following exposure from 0.03 to 0.47 microgram ml-1 (mean +/- s.e.mean 0.15 +/- 0.02). 3 The SSPC of PL before exposure to DPH varied from 1.2 to 4.4 microgram ml-1 (mean +/- s.e.mean 2.7 +/- 0.13), and following exposure from 1.1 to 3.8 microgram ml-1 (mean +/- s.e.mean 2.2 +/- 0.13). 4 SSPCs of AA and of PL decreased significantly during DPH administration (P less than 0.01 for AA, P less than 0.001 for PL). 5 Correlations were observed between the SSPCs of the drugs measured, suggesting a common influence on their kinetics. 6 Similarity was observed between the changes in plasma levels of AA and PL following DPH ingestion. There was, however, wide inter-subject variability in this regard. In some subjects no change was observed even though they had DPH demonstrable in their plasma. Consequently it may be speculated that the effects of DPH may be under genetic control.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7272175      PMCID: PMC1402207          DOI: 10.1111/j.1365-2125.1981.tb01175.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  9 in total

1.  Elimination of antipyrine and benzo[a]pyrene metabolism in cultured human lymphocytes.

Authors:  G Kellermann; M Luyten-Kellermann; M G Horning; M Stafford
Journal:  Clin Pharmacol Ther       Date:  1976-07       Impact factor: 6.875

2.  A method for the estimation of acetanilide, paracetamol and phenacetin in plasma and urine using mass fragmentography.

Authors:  J D Baty; P R Robinson; J Wharton
Journal:  Biomed Mass Spectrom       Date:  1976-04

3.  The pharmacokinetics of acetanilide and of diphenylhydantoin sodium.

Authors:  J L Cunningham; M F Bullen; D A Evans
Journal:  Eur J Clin Pharmacol       Date:  1974-10-04       Impact factor: 2.953

4.  Comparative drug elimination capacity in man-glutethimide, amobarbital, antipyrine, and sulfinpyrazone.

Authors:  D Kadar; T Inaba; L Endrenyi; G E Johnson; W Kalow
Journal:  Clin Pharmacol Ther       Date:  1973 Jul-Aug       Impact factor: 6.875

5.  Genetic variation of aryl hydrocarbon hydroxylase in human lymphocytes.

Authors:  G Kellermann; M Luyten-Kellermann; C R Shaw
Journal:  Am J Hum Genet       Date:  1973-05       Impact factor: 11.025

6.  Individual differences in the plasma half-lives of lipid soluble drugs in man.

Authors:  D S Davies; S S Thorgeirsson
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1971

7.  A comparative study of the metabolism of desmethylimipramine, nortriptyline, and oxyphenylbutazone in man.

Authors:  W Hammer; S Mårtens; F Sjöqvist
Journal:  Clin Pharmacol Ther       Date:  1969 Jan-Feb       Impact factor: 6.875

8.  Genetic control of the phenobarbital-induced shortening of plasma antipyrine half-lives in man.

Authors:  E S Vesell; J G Page
Journal:  J Clin Invest       Date:  1969-12       Impact factor: 14.808

9.  Inducibility of aryl hydrocarbon hydroxylase in cultured human lymphocytes: a study of repeatability.

Authors:  K A Fletcher; D A Evans; M V Canning
Journal:  J Med Genet       Date:  1978-06       Impact factor: 6.318

  9 in total
  2 in total

Review 1.  Pharmacokinetic drug interactions with phenytoin (Part II).

Authors:  R L Nation; A M Evans; R W Milne
Journal:  Clin Pharmacokinet       Date:  1990-02       Impact factor: 6.447

Review 2.  Pharmacokinetic interactions with antiepileptic drugs.

Authors:  E Perucca
Journal:  Clin Pharmacokinet       Date:  1982 Jan-Feb       Impact factor: 6.447

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.